Tissue plasminogen activator therapy for renal venous thrombosis.

Renal venous thrombosis (RVT) is a well recognized and potentially fatal entity in children. Approximately 80% of RVT present in the first month of life.1 Management of RVT remains controversial. Anticoagulation or thrombolytic therapy is recommended for bilateral RVT, unilateral RVT with extension of clot into the inferior vena cava, or impending renal failure.2 We report a case of bilateral RVT developed in a premature infant whom was treated with recombinant tissue plasminogen activator (r-TPA) and had a good outcome with eventual complete recovery.